← All companies
About this company
97% of all drug development projects fail before or during clinical trials. Especially for biologics, failures related to suboptimal candidates like insufficient potency, immunogenicity, toxic side effects or poor drug-like properties are the dominant cause of failure. nuantic provides AI-guided lead optimization to biotech companies seeking to increase their chances to overcome these hurdles and bring therapeutics to the market. We employ smart, highly efficient protein design algorithms to help to unlock innovative therapies, alleviate patient burden and reduce drug prices. The founding team currently consists of CEO Elias Hagmann (electrical engineer ETH, 12+ years of biotech industry experience) and CSO Dieter Schiegg (biochemist UZH, 13+ years of biotech industry experience).